<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-940
Date of Submission: 2025-01-31

This report was submitted by a Pharmacist from Hall-Hines Medical Center concerning patient ANON-PX-3094. The subject is a 77-year-old male with a significant medical history including coronary artery disease, atrial fibrillation, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 263mg, initiated on 2024-12-17 for Hypertension with the course ongoing; Warfarin administered via the Subcutaneous route at a dosage of 377mg, initiated on 2024-12-17 for Thromboembolism prevention with the course ongoing.

On approximately 2024-12-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Hepatotoxicity. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed name and advised live. The current patient status regarding this symptom is 'Unknown'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Treatment with discover hold current. Me phone campaign peace.</data>
report_id: ADR-2025-940
report_date: '2025-01-31'
patient_details:
  patient_id: ANON-PX-3094
  gender: Male
  relevant_history:
  - coronary artery disease
  - atrial fibrillation
  - seasonal allergies
  age_at_reaction: 77
suspected_drugs:
- drug_name: Lisinopril
  dosage: 263mg
  route_of_administration: Intravenous
  start_date: '2024-12-17'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
- drug_name: Warfarin
  dosage: 377mg
  route_of_administration: Subcutaneous
  start_date: '2024-12-17'
  indication_for_use: Thromboembolism prevention
adverse_reactions:
- symptom_name: Headache
  onset_date: '2024-12-25'
  severity: Moderate
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed name and advised live.
- symptom_name: Hepatotoxicity
  onset_date: '2024-12-25'
  severity: Moderate
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 1
reporting_facility: Hall-Hines Medical Center
reporter_type: Pharmacist
notes: Treatment with discover hold current. Me phone campaign peace.
